Namer M, Amiel J, Toubol J
Centre Antoine-Lacassagne, Nice, France.
Am J Clin Oncol. 1988;11 Suppl 2:S191-6. doi: 10.1097/00000421-198801102-00044.
A randomized, double-blind, multicenter trial was performed comparing the association of orchiectomy plus the nonsteroid antiandrogen Anandron (300 mg daily) to orchiectomy plus placebo in the treatment of patients with stage C or D prostate cancer. The results for 98 evaluable stage D patients with a median follow-up of 23.4 +/- 8.9 months are given. Although there was no statistically significant difference between the two treatments with regard to any parameter (subjective response, best objective response according to NPCP criteria, and progression-free interval and survival), the results were invariably in favor of the combined treatment, as already reported in other trials on Anandron.
进行了一项随机、双盲、多中心试验，比较睾丸切除术加非甾体抗雄激素药物安雄（每日300毫克）与睾丸切除术加安慰剂治疗C期或D期前列腺癌患者的疗效。给出了98例可评估的D期患者的结果，中位随访时间为23.4±8.9个月。尽管两种治疗在任何参数（主观反应、根据NPCP标准的最佳客观反应、无进展生存期和生存率）方面均无统计学显著差异，但结果始终有利于联合治疗，正如其他关于安雄的试验中所报道的那样。
